P05067

※ Protein Information

Tag	Content
UniProt Accession	A4_HUMAN; P05067;
Entrez ID	351
GenBank Protein ID	NM_000484.3; NM_001136016.3; NM_001136129.2; NM_001136130.2; NM_001136131.2; NM_001204301.1; NM_001204302.1; NM_001204303.1; NM_201413.2; NM_201414.2;
GenBank Nucleotide ID	NP_000475.1; NP_001129488.1; NP_001129601.1; NP_001129602.1; NP_001129603.1; NP_001191230.1; NP_001191231.1; NP_001191232.1; NP_958816.1; NP_958817.1;
Protein Name	Amyloid-beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Amyloid precursor protein) (Amyloid-beta precursor protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-a
Gene Name	APP; A4; AD1
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane recep(view all) Functional Description Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.;Amyloid-beta peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Amyloid-beta protein 42 is a more effective reductant than amyloid-beta protein 40. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. APP42-beta may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.;Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.;The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.;N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).
Sequence (Fasta)	MLPGLALLLL AAWTARALEV PTDGNAGLLA EPQIAMFCGR LNMHMNVQNG KWDSDPSGTK 60 TCIDTKEGIL QYCQEVYPEL QITNVVEANQ PVTIQNWCKR GRKQCKTHPH FVIPYRCLVG 120 EFVSDALLVP DKCKFLHQER MDVCETHLHW HTVAKETCSE KSTNLHDYGM LLPCGIDKFR 180 GVEFVCCPLA EESDNVDSAD AEEDDSDVWW GGADTDYADG SEDKVVEVAE EEEVAEVEEE 240 EADDDEDDED GDEVEEEAEE PYEEATERTT SIATTTTTTT ESVEEVVREV CSEQAETGPC 300 RAMISRWYFD VTEGKCAPFF YGGCGGNRNN FDTEEYCMAV CGSAMSQSLL KTTQEPLARD 360 PVKLPTTAAS TPDAVDKYLE TPGDENEHAH FQKAKERLEA KHRERMSQVM REWEEAERQA 420 KNLPKADKKA VIQHFQEKVE SLEQEAANER QQLVETHMAR VEAMLNDRRR LALENYITAL 480 QAVPPRPRHV FNMLKKYVRA EQKDRQHTLK HFEHVRMVDP KKAAQIRSQV MTHLRVIYER 540 MNQSLSLLYN VPAVAEEIQD EVDELLQKEQ NYSDDVLANM ISEPRISYGN DALMPSLTET 600 KTTVELLPVN GEFSLDDLQP WHSFGADSVP ANTENEVEPV DARPAADRGL TTRPGSGLTN 660 IKTEEISEVK MDAEFRHDSG YEVHHQKLVF FAEDVGSNKG AIIGLMVGGV VIATVIVITL 720 VMLKKKQYTS IHHGVVEVDA AVTPEERHLS KMQQNGYENP TYKFFEQMQN 771 Fasta Sequence >P05067\|APP; A4; AD1\|Homo sapiens (Human) MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN

※ PTM-Disease Association

Num	PTM	Disease	Type	PTM Site	PMID
1	Glycosylation	Alzheimer's disease	P		11447837; 24279329
1	[Reference]: For instance, -secretase and -secretase affect the extent of complex N-glycosylation and sialylation of APP, respectively. These processes may be important in AD pathogenesis, as proper intracellular sorting,?processing?and export of APP are affected by how it is glycosylated.
2	Palmitoylation	Alzheimer's disease	P	C186	23825420
2	[Reference]: our results indicate that APP palmitoylation enhances amyloidogenic?processing?by targeting APP to lipid rafts and enhancing its BACE1-mediated cleavage. Thus, inhibition of palAPP formation by ACAT or specific palmitoylation inhibitors would appear to be a valid strategy for prevention and/or treatment of AD.
3	Serine Phosphorylation	Alzheimer's disease	U	S679	25556395
3	[Reference]: Investigation of A? phosphorylated at serine 8 (pA?) in Alzheimer's disease, dementia with Lewy bodies and vascular dementia.
4	Threonine Phosphorylation	Alzheimer's disease	U	T729	17634293
4	[Reference]: The amyloid-beta precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration.
5	Threonine Phosphorylation	Alzheimer's disease	U	T743	14970211; 16705182
5	[Reference]: Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration.
6	Tyrosine Phosphorylation	Neuroblastoma	U	Y757	24349301
6	[Reference]: Increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)

※ Disease Cross-ref Annotation

Database	Annotation
CTD (Curated) (count: 25) (view all)	MESH:D019588 ; Aging, Premature MESH:D000544 ; Alzheimer Disease MESH:D000647 ; Amnesia MESH:D000686 ; Amyloidosis MESH:C537944 ; Amyloidosis, Cerebroarterial, App-Related MESH:D001008 ; Anxiety Disorders MESH:D001927 ; Brain Diseases MESH:D016657 ; Cerebral Amyloid Angiopathy MESH:D003072 ; Cognition Disorders MESH:D060825 ; Cognitive Dysfunction MESH:D003704 ; Dementia MESH:D004195 ; Disease Models, Animal MESH:D005600 ; Fragile X Syndrome MESH:D007859 ; Learning Disorders MESH:D008106 ; Liver Cirrhosis, Experimental MESH:D008569 ; Memory Disorders MESH:D009336 ; Necrosis MESH:D009410 ; Nerve Degeneration MESH:D019636 ; Neurodegenerative Diseases MESH:D020078 ; Neurogenic Inflammation MESH:D010243 ; Paralysis MESH:D058225 ; Plaque, Amyloid MESH:D013118 ; Spinal Cord Diseases MESH:D013163 ; Splenomegaly MESH:D015430 ; Weight Gain
DisGeNet (Curated) (count: 68) (view all)	C0002395; Alzheimer's Disease C0002622; Amnesia C0002726; Amyloidosis C0003469; Anxiety Disorders C0005586; Bipolar Disorder C0006111; Brain Diseases C0007786; Brain Ischemia C0009241; Cognition Disorders C0009421; Comatose C0009952; Febrile Convulsions C0011168; Deglutition Disorders C0011570; Mental Depression C0011573; Endogenous depression C0011581; Depressive disorder C0014544; Epilepsy C0016667; Fragile X Syndrome C0018681; Headache C0020580; Hypesthesia C0023186; Learning Disorders C0023893; Liver Cirrhosis, Experimental C0025261; Memory Disorders C0025362; Mental Retardation C0027066; Myoclonus C0027540; Necrosis C0027746; Nerve Degeneration C0030554; Paresthesia C0036572; Seizures C0037928; Spinal Cord Diseases C0038002; Splenomegaly C0038454; Cerebrovascular accident C0043094; Weight Gain C0085220; Cerebral Amyloid Angiopathy C0085400; Neurofibrillary degeneration (morphologic abnormality) C0149854; Cerebellar hemorrhage C0149931; Migraine Disorders C0231341; Premature aging syndrome C0233514; Abnormal behavior C0233794; Memory impairment C0242422; Parkinsonian Disorders C0268394; Hereditary Cerebral Amyloid Angiopathy, Dutch Type C0270685; Cerebral calcification C0338656; Impaired cognition C0423903; Low intelligence C0497327; Dementia C0522224; Paralysed C0524851; Neurodegenerative Disorders C0542476; Forgetful C0553692; Brain hemorrhage C0557874; Global developmental delay C0575081; Gait abnormality C0600467; Neurogenic Inflammation C0744641; Intermittent migraine headaches C0751295; Memory Loss C0917798; Cerebral Ischemia C0917816; Mental deficiency C1836791; Tortuous cerebral arteries C1843367; Poor school performance C1863051; ALZHEIMER DISEASE 2 C1864897; Cognitive delay C1865903; Long tract signs C2751536; CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED C2931672; Cerebral hemorrhage with amyloidosis, hereditary, Dutch type C2936349; Plaque, Amyloid C2937358; Cerebral Hemorrhage C3714756; Intellectual Disability C4020875; Mental and motor retardation C4020876; Dull intelligence C4025264; Recurrent cerebral hemorrhage
HGMD (count: 47) (view all)	CD082046; Alzheimer disease; Small deletions CN060187; Alzheimer disease with cerebral amyloid angiopathy; Gross insertions CN060188; Alzheimer disease with cerebral amyloid angiopathy; Gross insertions CN060189; Alzheimer disease with cerebral amyloid angiopathy; Gross insertions CN060190; Alzheimer disease with cerebral amyloid angiopathy; Gross insertions CN060191; Alzheimer disease with cerebral amyloid angiopathy; Gross insertions CN067320; Alzheimer disease with cerebral amyloid angiopathy; Gross insertions CN075889; Alzheimer disease with cerebral amyloid angiopathy; Gross insertions CN086153; Alzheimer disease; Gross insertions CP921146; Alzheimer disease; Small indels CM940077; Alzheimer disease; Missense/nonsense CM091531; Alzheimer disease; Missense/nonsense CM030642; Alzheimer disease; Missense/nonsense CM043740; Alzheimer disease; Missense/nonsense CM920065; Alzheimer disease; Missense/nonsense CM004235; Cerebral haemorrhage; Missense/nonsense CM920067; Alzheimer disease; Missense/nonsense CM920066; Alzheimer disease; Missense/nonsense CM011910; Cerebral amyloid angiopathy; Missense/nonsense CM053768; Cerebral haemorrhage; Missense/nonsense CM091683; Alzheimer disease ?; Missense/nonsense CM930033; Alzheimer disease; Missense/nonsense CM920068; Schizophrenia; Missense/nonsense CM002749; Alzheimer disease; Missense/nonsense CM021245; Alzheimer disease; Missense/nonsense CM990168; Alzheimer disease; Missense/nonsense CM014318; Alzheimer disease; Missense/nonsense CM024723; Alzheimer disease; Missense/nonsense CM970096; Alzheimer disease; Missense/nonsense CM082491; Alzheimer disease; Missense/nonsense CM910040; Alzheimer disease; Missense/nonsense CM003587; Alzheimer disease; Missense/nonsense CM910041; Alzheimer disease; Missense/nonsense CM910039; Alzheimer disease; Missense/nonsense CM091684; Alzheimer disease ?; Missense/nonsense CM091685; Alzheimer disease ?; Missense/nonsense CM000127; Alzheimer disease; Missense/nonsense CM063844; Alzheimer disease; Missense/nonsense CR062110; Alzheimer disease ?; Regulatory CR057416; Reduced expression, association with; Regulatory CR062111; Alzheimer disease; Regulatory CR062112; Alzheimer disease ?; Regulatory CR057417; Reduced expression, association with; Regulatory CR062113; Alzheimer disease ?; Regulatory CR062114; Alzheimer disease; Regulatory CR062115; Alzheimer disease; Regulatory CR071278; Alzheimer disease, association with; Regulatory
GWASdb (count: 70) (view all)	rs2089242; Urinary metabolites; kidney disease rs7280059; Multiple complex diseases; Null rs7280059; Gallstones; cholecystolithiasis rs2829976; LDL cholesterol; atherosclerosis\|coronary artery disease rs2829976; Cholesterol, total; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs2829978; Cholesterol, total; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs2829978; LDL cholesterol; atherosclerosis\|coronary artery disease rs3827216; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs7279104; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs11087984; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs2829996; Multiple complex diseases; Null rs2829997; Prostate cancer; prostate cancer rs216762; Cognitive test performance; cognitive disorder rs3787629; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs9636774; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs128648; Type 2 diabetes; type 2 diabetes mellitus rs128647; Amyotrophic lateral sclerosis (sporadic); amyotrophic lateral sclerosis rs7283500; Response to antidepressant treatment (citalopram); major depressive disorder rs2096488; Multiple complex diseases; Null rs7276036; Alcohol dependence; alcohol dependence rs2830026; Coronary artery calcification; coronary artery disease rs6516719; Coronary artery calcification; coronary artery disease rs2830031; Multiple complex diseases; Null rs9980729; Insulin resistance; type 2 diabetes mellitus rs7281821; Insulin resistance; type 2 diabetes mellitus rs2830045; Alcohol dependence; alcohol dependence rs2830050; Multiple complex diseases; Null rs2154481; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs2154481; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs2830054; Temporomandibular joint disorders; temporomandibular joint disorder\|myofascial pain syndrome rs2234988; Multiple complex diseases; Null rs2256331; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs2256331; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs2830066; Multiple complex diseases; Null rs2830066; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs2830066; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs2830068; Amyotrophic Lateral Sclerosis; amyotrophic lateral sclerosis rs9984764; Cholesterol, total; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs9984764; HDL cholesterol; cholesterol ester storage disease\|cholesterol embolism\|coronary artery disease rs2830073; Multiple complex diseases; Null rs2830075; Multiple complex diseases; Null rs2830076; Multiple complex diseases; Null rs2830077; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs2830077; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs432766; Multiple complex diseases; Null rs432766; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs432766; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs16997475; Schizophrenia; schizophrenia rs2830086; Multiple complex diseases; Null rs375369; Multiple complex diseases; Null rs375369; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs375369; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs2830088; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs2830088; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs2830089; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs2830089; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs467021; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs467021; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs2186302; Multiple complex diseases; Null rs2186302; Amyotrophic Lateral Sclerosis; amyotrophic lateral sclerosis rs2154482; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs2154482; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs12483003; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs12483003; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs436011; Multiple complex diseases; Null rs368196; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs368196; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs465235; Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months); rheumatoid arthritis rs465235; Methotrexate clearance (acute lymphoblastic leukemia); acute lymphocytic leukemia\|acute leukemia rs462281; Blood pressure; hypertension

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 15) (view all)	115 HPHFVIPYRCLVGEF dbPAF 198 EESDNVDSADAEEDD dbPAF 206 ADAEEDDSDVWWGGA dbPAF 378 TPDAVDKYLETPGDE dbPAF 381 AVDKYLETPGDENEH dbPAF 441 HFQEKVESLEQEAAN dbPAF 497 VFNMLKKYVRAEQKD dbPAF 679 DAEFRHDSGYEVHHQ dbPAF 728 VMLKKKQYTSIHHGV dbPAF 729 MLKKKQYTSIHHGVV dbPAF 730 LKKKQYTSIHHGVVE dbPAF 743 VEVDAAVTPEERHLS dbPAF 757 SKMQQNGYENPTYKF dbPAF 761 QNGYENPTYKFFEQM dbPAF 762 NGYENPTYKFFEQMQ dbPAF
Ubiquitination (count: 7) (view all)	132 DALLVPDKCKFLHQE PLMD 178 LLPCGIDKFRGVEFV PLMD 60 DSDPSGTKTCIDTKE PLMD 66 TKTCIDTKEGILQYC PLMD 751 PEERHLSKMQQNGYE PLMD 763 GYENPTYKFFEQMQN PLMD 99 VTIQNWCKRGRKQCK PLMD
Sumoylation (count: 3)	662 GSGLTNIKTEEISEV PLMD 670 TEEISEVKMDAEFRH PLMD 751 PEERHLSKMQQNGYE PLMD

※ Protein-Protein Interaction

Network

Interaction

Source

H0YGH4	P05067	IntAct
O00213	P05067	IntAct
O00468	P05067	IntAct
O14879	P05067	IntAct
O43399	P05067	IntAct
O75069	P05067	IntAct
O75509	P05067	IntAct
O75955	P05067	IntAct
O95704	P05067	IntAct
P01100	P05067	IntAct
P01137	P05067	IntAct
P02511	P05067	IntAct
P02647	P05067	IntAct
P02686	P05067	IntAct
P02768	P05067	BioGRID
P03897	P05067	IntAct
P04040	P05067	IntAct
P04156	P05067	IntAct
P05067	P05067	IntAct
P05067	P05412	IntAct
P05067	P07196	IntAct
P05067	P07437	IntAct
P05067	P07900	IntAct
P05067	P07996	IntAct
P05067	P08138	IntAct
P05067	P09936	IntAct
P05067	P10636	IntAct
P05067	P11142	IntAct
P05067	P13984	IntAct
P05067	P14136	IntAct
P05067	P17252	BioGRID
P05067	P18669	IntAct
P05067	P21359	IntAct
P05067	P21980	IntAct
P05067	P27797	IntAct
P05067	P29353	IntAct
P05067	P30101	IntAct
P05067	P35579	IntAct
P05067	P36544	IntAct
P05067	P39060	IntAct
P05067	P46459	IntAct
P05067	P46531	BioGRID
P05067	P49768	IntAct
P05067	P49810	IntAct
P05067	P49840	IntAct
P05067	P56817	IntAct
P05067	P58753	IntAct
P05067	P60709	IntAct
P05067	P61457	IntAct
P05067	P61764	IntAct
P05067	P61812	IntAct
P05067	P62937	IntAct
P05067	P63104	IntAct
P05067	P78536	IntAct
P05067	Q00987	IntAct
P05067	Q02410	IntAct
P05067	Q02817	BioGRID
P05067	Q05193	IntAct
P05067	Q13526	IntAct
P05067	Q13625	IntAct
P05067	Q13813	IntAct
P05067	Q13951	IntAct
P05067	Q16543	IntAct
P05067	Q16594	IntAct
P05067	Q5JRX3	IntAct
P05067	Q8TAG9	IntAct
P05067	Q92529	IntAct
P05067	Q92870	IntAct
P05067	Q92876	IntAct
P05067	Q96QH2	IntAct
P05067	Q99683	IntAct
P05067	Q99714	IntAct
P05067	Q9H0A6	IntAct
P05067	Q9NP59	IntAct
P05067	Q9P2D7	IntAct
P05067	Q9UQF2	IntAct
P05067	Q9Y2H9	IntAct
P05067	Q9Y6Q5	IntAct

PTMD Annotation Information

※ Protein Information

Functional Description

Fasta Sequence

※ PTM-Disease Association

※ Disease Cross-ref Annotation

※ PTM Sites

※ Protein-Protein Interaction